Pictured: Oliver Zivanovic, Garrett Nash & Dennis Chi
In the Clinic
By Esther Napolitano, BS, Science Writer/Editor  |  Friday, November 15, 2013

Memorial Sloan Kettering experts are leading investigations of a procedure called hyperthermic intraperitoneal chemotherapy, also known as HIPEC.

Pictured: Lawrence Dauer
In the O.R.
By Media Staff  |  Tuesday, September 10, 2013

Memorial Sloan Kettering clinicians report on a successful first year of using a new procedure to pinpoint and remove small breast cancers.

Pictured: Robert J. Motzer
In the Clinic
By Maureen Salamon, BA, Freelance Writer  |  Thursday, August 22, 2013

An international study led by Memorial Sloan Kettering found that pazopanib (Votrient®) controls cancer as effectively as sunitinib (Sutent®) while improving patients’ quality of life.

Pictured: Micropapillary Morphology
In the Lab
By Esther Napolitano, BS, Science Writer/Editor  |  Friday, August 9, 2013

A Memorial Sloan Kettering study shows that an abnormal cell pattern found in the tumor tissue of some lung cancer patients may help to predict which tumors are more likely to recur after surgery.

In the Clinic
By Memorial Sloan Kettering  |  Wednesday, June 19, 2013

A Memorial Sloan Kettering study suggests that lymphedema of the arm, a swelling that can occur following breast cancer treatment, may be reduced by acupuncture.

Pictured: Jedd Wolchok & Richard Carvajal
In the Clinic
By Media Staff  |  Monday, June 3, 2013

Two Memorial Sloan Kettering studies that hold promise for the treatment of advanced uveal (eye) melanoma and advanced skin melanoma are making headlines at the 49th Annual Meeting of the American Society of Clinical Oncology.

Pictured: Paul Russo
In the Clinic
By Media Staff  |  Monday, May 20, 2013

A study has found that the majority of kidney cancer patients with small tumors have their entire kidney removed, which can increase the risk of developing chronic kidney disease and cardiovascular complications.

Pictured: Gary Schwartz & Mark Dickson
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Monday, April 22, 2013

Two clinical trials of targeted therapies led by Memorial Sloan Kettering investigators show promising results against different types of sarcoma.

Pictured: Jedd Wolchok
In the Clinic
By Media Staff  |  Thursday, April 4, 2013

Early research led by investigators at Memorial Sloan Kettering cautions against combining ipilimumab and vemurafenib for the treatment of metastatic melanoma.

Pictured: Isabelle Rivière, Michel Sadelain & Renier Brentjens
In the Clinic
By Jim Stallard, MA, Writer/Editor  |  Wednesday, March 20, 2013

Memorial Sloan Kettering researchers have used genetically modified immune cells to eradicate cancer in five patients with acute lymphoblastic leukemia.

Pictured: James Fagin
In the Clinic
By Media Staff  |  Thursday, February 14, 2013

Researchers have found that the investigational drug selumetinib shuts down the signaling of genetic mutations that prevent some patients’ thyroid cancer tumors from absorbing radioiodine, the most effective treatment for the disease.

Pictured: Kenneth Yu
In the Clinic
By Media Staff  |  Tuesday, January 29, 2013

New research suggests that analyzing genetic changes found in the bloodstream may help doctors predict which chemotherapy regimens will work for some patients.

Pictured: Mark Bilsky
In the O.R.
By Jim Stallard, MA, Writer/Editor  |  Friday, January 25, 2013

Our doctors have shown that tumors compressing the spinal cord can be controlled using less-invasive surgery combined with a precise, intense form of radiation therapy.

Pictured: Marcel R. M. van den Brink
In the Clinic
By Jim Stallard, MA, Writer/Editor  |  Friday, December 21, 2012

Memorial Sloan Kettering researchers have shown for the first time that administering a growth factor called interleukin-7 can help patients regenerate T cells more quickly after stem cell transplantation.

Pictured: Paul Chapman
Finding
By Memorial Sloan Kettering  |  Friday, December 7, 2012

Memorial Sloan Kettering experts add to their knowledge of vemurafenib, a drug recently approved by the FDA to treat some patients with metastatic melanoma.

Center News

Stay Informed

Get the latest information about cancer care and research every month.